Juno Turns to Immuno-Oncology Combinations with Acquisition of RedoxTherapies
By Dan Roberts
Pharma Deals Review: Vol 2016 Issue 7 (Table of Contents)
Published: 28 Jul-2016
DOI: 10.3833/pdr.v2016.i7.2178 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Juno Therapeutics, a company which specialises in cellular cancer immunotherapies, especially chimeric antigen receptors (CARs) and T-cell receptors (TCRs), expands its portfolio to small molecule modulators with its acquisition of RedoxTherapies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS